361 related articles for article (PubMed ID: 23978337)
1. Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.
Kerlan V; Gouet D; Marre M; Renard É
Ann Endocrinol (Paris); 2013 Dec; 74(5-6):487-90. PubMed ID: 23978337
[TBL] [Abstract][Full Text] [Related]
2. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.
Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B
Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727
[TBL] [Abstract][Full Text] [Related]
4. The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design.
Agesen RM; Alibegovic AC; Andersen HU; Beck-Nielsen H; Gustenhoff P; Hansen TK; Hedetoft C; Jensen T; Juhl CB; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
BMC Endocr Disord; 2019 Jul; 19(1):78. PubMed ID: 31337371
[TBL] [Abstract][Full Text] [Related]
5. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Heller S; Buse J; Fisher M; Garg S; Marre M; Merker L; Renard E; Russell-Jones D; Philotheou A; Francisco AM; Pei H; Bode B;
Lancet; 2012 Apr; 379(9825):1489-97. PubMed ID: 22521071
[TBL] [Abstract][Full Text] [Related]
6. Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
Berard L; MacNeill G
Can J Diabetes; 2015 Feb; 39(1):4-9. PubMed ID: 25065475
[TBL] [Abstract][Full Text] [Related]
7. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Garber AJ; King AB; Del Prato S; Sreenan S; Balci MK; Muñoz-Torres M; Rosenstock J; Endahl LA; Francisco AM; Hollander P;
Lancet; 2012 Apr; 379(9825):1498-507. PubMed ID: 22521072
[TBL] [Abstract][Full Text] [Related]
8. Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non-interventional study (EU-TREAT).
Knudsen ST; Lapolla A; Schultes B; Tentolouris N; Catarig AM; Wolden ML; Siegmund T
Diabet Med; 2019 Jul; 36(7):868-877. PubMed ID: 31001865
[TBL] [Abstract][Full Text] [Related]
9. Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.
Muñoz Torres M
Endocrinol Nutr; 2014 Mar; 61(3):153-9. PubMed ID: 23890782
[TBL] [Abstract][Full Text] [Related]
10. Treating to target in type 2 diabetes: the BEGIN trial programme.
Wangnoo SK; Chowdhury S; Rao PV
J Assoc Physicians India; 2014 Jan; 62(1 Suppl):21-6. PubMed ID: 25330628
[TBL] [Abstract][Full Text] [Related]
11. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.
Bode BW; Buse JB; Fisher M; Garg SK; Marre M; Merker L; Renard E; Russell-Jones DL; Hansen CT; Rana A; Heller SR;
Diabet Med; 2013 Nov; 30(11):1293-7. PubMed ID: 23710902
[TBL] [Abstract][Full Text] [Related]
12. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.
Sorli C; Warren M; Oyer D; Mersebach H; Johansen T; Gough SC
Drugs Aging; 2013 Dec; 30(12):1009-18. PubMed ID: 24170235
[TBL] [Abstract][Full Text] [Related]
13. Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials.
Preumont V; Buysschaert M
Diabetes Metab; 2020 Apr; 46(2):83-88. PubMed ID: 31055056
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.
Zinman B; DeVries JH; Bode B; Russell-Jones D; Leiter LA; Moses A; Johansen T; Ratner R;
Lancet Diabetes Endocrinol; 2013 Oct; 1(2):123-31. PubMed ID: 24622318
[TBL] [Abstract][Full Text] [Related]
15. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials.
Zhang XW; Zhang XL; Xu B; Kang LN
Acta Diabetol; 2018 May; 55(5):429-441. PubMed ID: 29423761
[TBL] [Abstract][Full Text] [Related]
16. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
Heller SR; DeVries JH; Wysham C; Hansen CT; Hansen MV; Frier BM
Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886
[TBL] [Abstract][Full Text] [Related]
17. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
[TBL] [Abstract][Full Text] [Related]
18. Basal insulin analogues in the management of diabetes mellitus: What progress have we made?
Owens DR; Matfin G; Monnier L
Diabetes Metab Res Rev; 2014 Feb; 30(2):104-19. PubMed ID: 24026961
[TBL] [Abstract][Full Text] [Related]
19. Understanding the safety of the new ultra long acting basal insulin.
Ramachandran A; Gupta V; Kesavadev J; Kalra S
J Assoc Physicians India; 2014 Jan; 62(1 Suppl):35-42. PubMed ID: 25330630
[TBL] [Abstract][Full Text] [Related]
20. Insulin degludec. Uncertainty over cardiovascular harms.
Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
